2023
Start preparing for regulatory declaration
- Developing various oligosaccharides such as 2 '- FL, 3-FL, 3' - SL, 6 '- SL, LNT, and LNnT in the HMOs family. Among them, the production and indicators of LNT and LNnT products have reached industry-leading levels, and the process has been scaled up,
- Preparation for HMOs national regulatory declaration.
2023.07-2023.09
Building a research and development platform and establishing a company
- On August 7th, Shenzhen Zhongke Langjian Biotechnology Co., Ltd. was registered and established with a registered capital of 45 million yuan
- The construction of cutting-edge platforms such as AI bioinformatics and microfluidics has been completed
2023.09-2023.11
Multi party cooperation deepens in the field of synthetic biology
- Cooperate with the Shenzhen Advanced Institute of the Chinese Academy of Sciences and other institutions to jointly establish the National Biomedical Manufacturing Industry Innovation Center
- Cooperate with Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, and participate in the Angel Fund for Synthetic Biology
2023. 11-2024. 12
Site selection for production line and construction of 260 ton production line
- In January 2024, LNT+LNnT passed the safety review of bacterial strains by the Ministry of Agriculture
- Expected to be approved as a new variety of food nutrition fortifier in October 2024
- Expected to complete the first phase of the 260 ton HMOs production line by November 2024
